Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59


Discovery of BI 207524, an indole diamide NS5B thumb pocket 1 inhibitor with improved potency for the potential treatment of chronic hepatitis C virus infection.

Beaulieu PL, Anderson PC, Bethell R, Bös M, Bousquet Y, Brochu C, Cordingley MG, Fazal G, Garneau M, Gillard JR, Kawai S, Marquis M, McKercher G, Poupart MA, Stammers T, Thavonekham B, Wernic D, Duan J, Kukolj G.

J Med Chem. 2014 Dec 11;57(23):10130-43. doi: 10.1021/jm501532z. Epub 2014 Nov 25.


CD160 isoforms and regulation of CD4 and CD8 T-cell responses.

El-Far M, Pellerin C, Pilote L, Fortin JF, Lessard IA, Peretz Y, Wardrop E, Salois P, Bethell RC, Cordingley MG, Kukolj G.

J Transl Med. 2014 Sep 2;12:217. doi: 10.1186/s12967-014-0217-y.


Identification of potent and orally bioavailable nucleotide competing reverse transcriptase inhibitors: in vitro and in vivo optimization of a series of benzofurano[3,2-d]pyrimidin-2-one derived inhibitors.

Sturino CF, Bousquet Y, James CA, DeRoy P, Duplessis M, Edwards PJ, Halmos T, Minville J, Morency L, Morin S, Thavonekham B, Tremblay M, Duan J, Ribadeneira M, Garneau M, Pelletier A, Tremblay S, Lamorte L, Bethell R, Cordingley MG, Rajotte D, Simoneau B.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3967-75. doi: 10.1016/j.bmcl.2013.04.043. Epub 2013 Apr 25.


Identification of benzofurano[3,2-d]pyrimidin-2-ones, a new series of HIV-1 nucleotide-competing reverse transcriptase inhibitors.

Tremblay M, Bethell RC, Cordingley MG, DeRoy P, Duan J, Duplessis M, Edwards PJ, Faucher AM, Halmos T, James CA, Kuhn C, Lacoste JÉ, Lamorte L, LaPlante SR, Malenfant E, Minville J, Morency L, Morin S, Rajotte D, Salois P, Simoneau B, Tremblay S, Sturino CF.

Bioorg Med Chem Lett. 2013 May 1;23(9):2775-80. doi: 10.1016/j.bmcl.2013.02.042. Epub 2013 Feb 16.


Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target.

Vaillancourt FH, Brault M, Pilote L, Uyttersprot N, Gaillard ET, Stoltz JH, Knight BL, Pantages L, McFarland M, Breitfelder S, Chiu TT, Mahrouche L, Faucher AM, Cartier M, Cordingley MG, Bethell RC, Jiang H, White PW, Kukolj G.

J Virol. 2012 Nov;86(21):11595-607. doi: 10.1128/JVI.01320-12. Epub 2012 Aug 15.


The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in humans.

Duan J, Bolger G, Garneau M, Amad M, Batonga J, Montpetit H, Otis F, Jutras M, Lapeyre N, Rhéaume M, Kukolj G, White PW, Bethell RC, Cordingley MG.

Antimicrob Agents Chemother. 2012 Oct;56(10):5381-6. doi: 10.1128/AAC.01028-12. Epub 2012 Aug 6.


Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).

Beaulieu PL, Bös M, Cordingley MG, Chabot C, Fazal G, Garneau M, Gillard JR, Jolicoeur E, LaPlante S, McKercher G, Poirier M, Poupart MA, Tsantrizos YS, Duan J, Kukolj G.

J Med Chem. 2012 Sep 13;55(17):7650-66. doi: 10.1021/jm3006788. Epub 2012 Aug 16.


Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor.

Duan J, Yong CL, Garneau M, Amad M, Bolger G, De Marte J, Montpetit H, Otis F, Jutras M, Rhéaume M, White PW, Llinàs-Brunet M, Bethell RC, Cordingley MG.

Xenobiotica. 2012 Feb;42(2):164-72. doi: 10.3109/00498254.2011.611546. Epub 2011 Oct 11.


Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly.

Fader LD, Bethell R, Bonneau P, Bös M, Bousquet Y, Cordingley MG, Coulombe R, Deroy P, Faucher AM, Gagnon A, Goudreau N, Grand-Maître C, Guse I, Hucke O, Kawai SH, Lacoste JE, Landry S, Lemke CT, Malenfant E, Mason S, Morin S, O'Meara J, Simoneau B, Titolo S, Yoakim C.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):398-404. doi: 10.1016/j.bmcl.2010.10.131. Epub 2010 Oct 31.


Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.

White PW, Llinàs-Brunet M, Amad M, Bethell RC, Bolger G, Cordingley MG, Duan J, Garneau M, Lagacé L, Thibeault D, Kukolj G.

Antimicrob Agents Chemother. 2010 Nov;54(11):4611-8. doi: 10.1128/AAC.00787-10. Epub 2010 Sep 7.


Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335).

Llinàs-Brunet M, Bailey MD, Goudreau N, Bhardwaj PK, Bordeleau J, Bös M, Bousquet Y, Cordingley MG, Duan J, Forgione P, Garneau M, Ghiro E, Gorys V, Goulet S, Halmos T, Kawai SH, Naud J, Poupart MA, White PW.

J Med Chem. 2010 Sep 9;53(17):6466-76. doi: 10.1021/jm100690x.


Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication.

Vaillancourt FH, Pilote L, Cartier M, Lippens J, Liuzzi M, Bethell RC, Cordingley MG, Kukolj G.

Virology. 2009 Apr 25;387(1):5-10. doi: 10.1016/j.virol.2009.02.039. Epub 2009 Mar 21.


Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.

Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG.

Antiviral Res. 2005 Oct;68(1):27-35.


Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.

O'Meara JA, Yoakim C, Bonneau PR, Bös M, Cordingley MG, Déziel R, Doyon L, Duan J, Garneau M, Guse I, Landry S, Malenfant E, Naud J, Ogilvie WW, Thavonekham B, Simoneau B.

J Med Chem. 2005 Aug 25;48(17):5580-8.


A novel model of HPV infection in meshed human foreskin grafts.

Duan J, De Marte J, Paris W, Roopchand D, Fleet TL, Clarke JA, Yeong SH, Ferenczy A, Katz M, Cordingley MG.

Antiviral Res. 2004 Dec;64(3):179-88.


Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase.

Liuzzi M, Kibler P, Bousquet C, Harji F, Bolger G, Garneau M, Lapeyre N, McCollum RS, Faucher AM, Simoneau B, Cordingley MG.

Antiviral Res. 2004 Dec;64(3):161-70.


Experiences from the structure determination of human cytomegalovirus protease.

Tong L, Qian C, Davidson W, Massariol MJ, Bonneau PR, Cordingley MG, Lagacé L.

Acta Crystallogr D Biol Crystallogr. 1997 Nov 1;53(Pt 6):682-90.


Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.

Yoakim C, Bonneau PR, Déziel R, Doyon L, Duan J, Guse I, Landry S, Malenfant E, Naud J, Ogilvie WW, O'Meara JA, Plante R, Simoneau B, Thavonekham B, Bös M, Cordingley MG.

Bioorg Med Chem Lett. 2004 Feb 9;14(3):739-42.


An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.

Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bös M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagacé L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinàs-Brunet M.

Nature. 2003 Nov 13;426(6963):186-9. Epub 2003 Oct 26. Erratum in: Nature. 2003 Nov 20;246.


HPMPC therapy of MCMV-induced retinal disease in the SCID mouse measured by electroretinography, a non-invasive technique.

Garneau M, Bolger GT, Bousquet C, Kibler P, Tremblay F, Cordingley MG.

Antiviral Res. 2003 Aug;59(3):193-200.


Discovery of the first series of inhibitors of human papillomavirus type 11: inhibition of the assembly of the E1-E2-Origin DNA complex.

Yoakim C, Ogilvie WW, Goudreau N, Naud J, Haché B, O'Meara JA, Cordingley MG, Archambault J, White PW.

Bioorg Med Chem Lett. 2003 Aug 4;13(15):2539-41.


Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.

Duan J, Liuzzi M, Paris W, Liard F, Browne A, Dansereau N, Simoneau B, Faucher AM, Cordingley MG.

Antimicrob Agents Chemother. 2003 Jun;47(6):1798-804.


Inhibition of human papillomavirus DNA replication by small molecule antagonists of the E1-E2 protein interaction.

White PW, Titolo S, Brault K, Thauvette L, Pelletier A, Welchner E, Bourgon L, Doyon L, Ogilvie WW, Yoakim C, Cordingley MG, Archambault J.

J Biol Chem. 2003 Jul 18;278(29):26765-72. Epub 2003 Apr 30.


Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.

Crute JJ, Grygon CA, Hargrave KD, Simoneau B, Faucher AM, Bolger G, Kibler P, Liuzzi M, Cordingley MG.

Nat Med. 2002 Apr;8(4):386-91.


Discovery, total synthesis, HRV 3C-protease inhibitory activity, and structure-activity relationships of 2-methoxystypandrone and its analogues.

Singh SB, Graham PL, Reamer RA, Cordingley MG.

Bioorg Med Chem Lett. 2001 Dec 17;11(24):3143-6.


Characterization of recombinant HPV6 and 11 E1 helicases: effect of ATP on the interaction of E1 with E2 and mapping of a minimal helicase domain.

White PW, Pelletier A, Brault K, Titolo S, Welchner E, Thauvette L, Fazekas M, Cordingley MG, Archambault J.

J Biol Chem. 2001 Jun 22;276(25):22426-38. Epub 2001 Apr 13.


Identification of domains of the human papillomavirus type 11 E1 helicase involved in oligomerization and binding to the viral origin.

Titolo S, Pelletier A, Pulichino AM, Brault K, Wardrop E, White PW, Cordingley MG, Archambault J.

J Virol. 2000 Aug;74(16):7349-61.


Identification of domains of the HPV11 E1 protein required for DNA replication in vitro.

Amin AA, Titolo S, Pelletier A, Fink D, Cordingley MG, Archambault J.

Virology. 2000 Jun 20;272(1):137-50.


Topical effects of cidofovir on cutaneous rabbit warts: treatment regimen and inoculum dependence.

Duan J, Paris W, De Marte J, Roopchand D, Fleet TL, Cordingley MG.

Antiviral Res. 2000 May;46(2):135-44.


Role of the ATP-binding domain of the human papillomavirus type 11 E1 helicase in E2-dependent binding to the origin.

Titolo S, Pelletier A, Sauvé F, Brault K, Wardrop E, White PW, Amin A, Cordingley MG, Archambault J.

J Virol. 1999 Jul;73(7):5282-93.


Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice.

Duan J, Paris W, Kibler P, Bousquet C, Liuzzi M, Cordingley MG.

Antiviral Res. 1998 Oct;39(3):189-97.


Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.

Duan J, Liuzzi M, Paris W, Lambert M, Lawetz C, Moss N, Jaramillo J, Gauthier J, Déziel R, Cordingley MG.

Antimicrob Agents Chemother. 1998 Jul;42(7):1629-35.


Improved purification protocol of the HSV-1 protease catalytic domain, using immunoaffinity.

McKercher G, Bonneau PR, Lagacé L, Thibeault D, Massariol MJ, Krogsrud R, Lawetz C, McDonald PC, Cordingley MG.

Biochem Cell Biol. 1997;75(6):795-801.


A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease.

Tong L, Qian C, Massariol MJ, Bonneau PR, Cordingley MG, Lagacé L.

Nature. 1996 Sep 19;383(6597):272-5.


Differential steroid hormone induction of transcription from the mouse mammary tumor virus promoter.

Archer TK, Lee HL, Cordingley MG, Mymryk JS, Fragoso G, Berard DS, Hager GL.

Mol Endocrinol. 1994 May;8(5):568-76.


The herpes simplex virus type 1 DNA polymerase accessory protein, UL42, contains a functional protease-resistant domain.

Hamatake RK, Bifano M, Tenney DJ, Hurlburt WW, Cordingley MG.

J Gen Virol. 1993 Oct;74 ( Pt 10):2181-9.


Autoproteolysis of herpes simplex virus type 1 protease releases an active catalytic domain found in intermediate capsid particles.

Weinheimer SP, McCann PJ 3rd, O'Boyle DR 2nd, Stevens JT, Boyd BA, Drier DA, Yamanaka GA, DiIanni CL, Deckman IC, Cordingley MG.

J Virol. 1993 Oct;67(10):5813-22.


The C-terminal third of UL42, a HSV-1 DNA replication protein, is dispensable for viral growth.

Gao M, DiTusa SF, Cordingley MG.

Virology. 1993 Jun;194(2):647-53.


Deletions of the carboxy terminus of herpes simplex virus type 1 UL42 define a conserved amino-terminal functional domain.

Tenney DJ, Hurlburt WW, Bifano M, Stevens JT, Micheletti PA, Hamatake RK, Cordingley MG.

J Virol. 1993 Apr;67(4):1959-66.


Identification of the herpes simplex virus-1 protease cleavage sites by direct sequence analysis of autoproteolytic cleavage products.

DiIanni CL, Drier DA, Deckman IC, McCann PJ 3rd, Liu F, Roizman B, Colonno RJ, Cordingley MG.

J Biol Chem. 1993 Jan 25;268(3):2048-51.


Mutations in the C terminus of herpes simplex virus type 1 DNA polymerase can affect binding and stimulation by its accessory protein UL42 without affecting basal polymerase activity.

Tenney DJ, Micheletti PA, Stevens JT, Hamatake RK, Matthews JT, Sanchez AR, Hurlburt WW, Bifano M, Cordingley MG.

J Virol. 1993 Jan;67(1):543-7.


Structural implications of spectroscopic characterization of a putative zinc finger peptide from HIV-1 integrase.

Burke CJ, Sanyal G, Bruner MW, Ryan JA, LaFemina RL, Robbins HL, Zeft AS, Middaugh CR, Cordingley MG.

J Biol Chem. 1992 May 15;267(14):9639-44.


Substrate specificity of recombinant human immunodeficiency virus integrase protein.

LaFemina RL, Callahan PL, Cordingley MG.

J Virol. 1991 Oct;65(10):5624-30.


Sequence-specific interaction of Tat protein and Tat peptides with the transactivation-responsive sequence element of human immunodeficiency virus type 1 in vitro.

Cordingley MG, LaFemina RL, Callahan PL, Condra JH, Sardana VV, Graham DJ, Nguyen TM, LeGrow K, Gotlib L, Schlabach AJ, et al.

Proc Natl Acad Sci U S A. 1990 Nov;87(22):8985-9.


Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro.

Cordingley MG, Callahan PL, Sardana VV, Garsky VM, Colonno RJ.

J Biol Chem. 1990 Jun 5;265(16):9062-5.

Supplemental Content

Loading ...
Support Center